Privia Health Group (NASDAQ:PRVA) CEO Sells $479,112.87 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 21,097 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $22.71, for a total transaction of $479,112.87. Following the completion of the transaction, the chief executive officer owned 322,698 shares of the company’s stock, valued at approximately $7,328,471.58. The trade was a 6.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Parth Mehrotra also recently made the following trade(s):

• On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The shares were sold at an average price of $22.86, for a total value of $960,097.14.
• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $496,336.00.

Privia Health Group Stock Down 1.5%

Shares of Privia Health Group stock traded down $0.34 on Thursday, reaching $21.73. The company’s stock had a trading volume of 691,872 shares, compared to its average volume of 816,399. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51. The firm’s fifty day simple moving average is $22.97 and its two-hundred day simple moving average is $23.60. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 127.82, a P/E/G ratio of 1.42 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. During the same period in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, research analysts predict that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Trading of Privia Health Group

Several institutional investors and hedge funds have recently modified their holdings of the company. Great Lakes Advisors LLC bought a new position in shares of Privia Health Group in the third quarter worth about $4,487,000. Advantage Alpha Capital Partners LP bought a new stake in Privia Health Group during the 2nd quarter valued at approximately $3,941,000. Hsbc Holdings PLC raised its stake in Privia Health Group by 69.2% during the 2nd quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock valued at $2,549,000 after purchasing an additional 46,526 shares during the period. Edgestream Partners L.P. purchased a new position in Privia Health Group in the 2nd quarter worth approximately $2,209,000. Finally, Bailard Inc. bought a new position in Privia Health Group in the 2nd quarter worth approximately $531,000. 94.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PRVA has been the topic of several research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Monday, December 29th. Wolfe Research set a $31.00 price target on shares of Privia Health Group in a research note on Tuesday, January 6th. BMO Capital Markets began coverage on shares of Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Privia Health Group in a research report on Friday, January 9th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Citigroup decreased their target price on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.